Literature DB >> 8386068

Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease.

N Barroso1, Y Campos, R Huertas, J Esteban, J A Molina, A Alonso, E Gutierrez-Rivas, J Arenas.   

Abstract

Respiratory chain enzyme activities were studied in lymphocytes from patients with Parkinson disease (PD) (n = 16) and age-matched control subjects (n = 15). The patients had received no therapy before the study was conducted. Complex I, III, and IV activities were significantly lower (P < 0.05) in patients than in control subjects. A complex I defect was found in one patient, whereas complex IV was defective in another. Two patients had combined defects of both complexes. The use of lymphocytes for investigating the respiratory chain enzymes provides an easy, noninvasive method to assess mitochondrial function in patients with PD. Furthermore, our study supports the hypothesis that a biochemical defect in the respiratory chain may be involved in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386068

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  23 in total

Review 1.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 2.  Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

3.  Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease.

Authors:  André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason
Journal:  Gut Pathog       Date:  2009-11-26       Impact factor: 4.181

4.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

5.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy.

Authors:  Francesca R Buttarelli; Annapia Circella; Clelia Pellicano; Dorina Tiple; Morena Giovannelli; Carlo Colosimo; Francesco E Pontieri
Journal:  J Neural Transm (Vienna)       Date:  2008-12-17       Impact factor: 3.575

Review 6.  Mitochondrial dynamics in Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Exp Neurol       Date:  2009-03-28       Impact factor: 5.330

Review 7.  Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.

Authors:  Laszlo Tretter; Ildiko Sipos; Vera Adam-Vizi
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

Review 8.  To live or to die: a matter of processing damaged DNA termini in neurons.

Authors:  Sherif F El-Khamisy
Journal:  EMBO Mol Med       Date:  2011-01-19       Impact factor: 12.137

9.  Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease.

Authors:  Pilar del Hoyo; Alberto García-Redondo; Fernando de Bustos; José Antonio Molina; Youssef Sayed; Hortensia Alonso-Navarro; Luis Caballero; Joaquín Arenas; Félix Javier Jiménez-Jiménez
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 4.414

10.  Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease.

Authors:  Pilar del Hoyo; Alberto García-Redondo; Fernando de Bustos; José Antonio Molina; Youssef Sayed; Hortensia Alonso-Navarro; Luis Caballero; Joaquín Arenas; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  BMC Neurol       Date:  2010-10-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.